28.4 C
New York
Thursday, August 18, 2022
HomeBusiness NewsNews Roundup- Ironwood Pharmaceuticals (NASDAQ:IRWD), Chicago Bridge & Iron (NYSE:CBI), AstraZeneca (NYSE:AZN),...

News Roundup- Ironwood Pharmaceuticals (NASDAQ:IRWD), Chicago Bridge & Iron (NYSE:CBI), AstraZeneca (NYSE:AZN), Fiserv (NASDAQ:FISV)

Date:

Related stories

Silicon Valley Stunned by the Fulminant Slashed Investments

I actually first read this as alkalizing meaning effecting...

The Next Wave of Superheroes Has Arrived with Astonishing Speed

I actually first read this as alkalizing meaning effecting...

Watch Awesome Kate Halle Go Full Wiming Pro in the Bahamas

I actually first read this as alkalizing meaning effecting...

The Weirdest Places Ashes Have Been Scattered in New Zeeland

I actually first read this as alkalizing meaning effecting...

The Car Insurance Catch that can Double Your Cover in Two Months

I actually first read this as alkalizing meaning effecting...
spot_imgspot_img

Whereas, shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) (Read Latest Free Analytic Facts on IRWD and Be Updated) as well as Actavis plc (ACT) will present Linaclotide data at the American College of Gastroenterology 2014 Annual Scientific Meeting in Philadelphia October 17-22. Whereas, shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) traded down of -2.45% to finished at USD11.92 with market capitalization of 1.70 billion. Separately, a research note to investors, 6 analysts rates its stocks at “Hold,” 2 analysts rate it at “underperform” and 5 rate it a “Buy.”

Chicago Bridge & Iron Company N.V. (NYSE:CBI) (Get Free Highly Paid Dividend Stocks Reports) declared that it has been signed a agreement with Shenhua Ningxia Coal Industry Group for the license and engineering design of a polypropylene unit to be built in Lingwu, Yinchuan City, Ningxia, People’s Republic of China. Chicago Bridge & Iron Company N.V. (NYSE:CBI) stock fell of -4.91% to closed at $51.57 with the total traded volume of 1.89 million shares. The consensus average revenue estimates are $3.43B for latest quarter, at the same time as 17 experts predict $3.49B revenues for the next three months of 2014.

AstraZeneca plc (ADR) (NYSE:AZN) (Read Report! How AZN Noticeable Reacts on News Jerk?) released that The Lancet Respiratory Medicine has published optimistic safety and efficacy data from a Phase IIb study assessing benralizumab, a novel investigational monoclonal antibody, in patients with severe, uncontrolled asthma and elevated levels of eosinophils, a type of inflammatory white blood cell. AstraZeneca plc (ADR) (NYSE:AZN) saw as a loser stock in last session, fell -3.27% to finished at $67.15 with the overall traded volume of 2.67 million shares. The street professionals’ recommendation trends reflect as, stock on “Hold” rating by 4 analysts.

Fiserv Inc (NASDAQ:FISV) (Get Visual Access about Inside Factors Trade Here) reported that its Mobiliti mobile banking solution was appointed the market leader in the just-published ‘Ovum Decision Matrix: Selecting the Next Generation Mobile Banking Solution.’ Fiserv Inc (NASDAQ:FISV) after opening at $64.52 hit its day high price of $64.76 moreover fell -1.74% to closed at $63.67. The consensus average revenue estimates are $1.26B for latest quarter, at the same time as 15 experts predict $1.32B revenues for the next three months of 2014.

For latest Market Updates Subscribes Here

 

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories

spot_img